Therma Bright Welcomes Healthcare and Technology Expert Steve Raysely to its Advisory Board
Rhea-AI Summary
Therma Bright (TSXV: THRM) (OTCQB: TBRIF) has appointed Steve Raysely to its Advisory Board, bringing over two decades of experience in healthcare and technology. Raysely, known for scaling businesses and building market strategies, specializes in medical device sales, AI-driven healthcare solutions, and strategic partnerships.
The company also announced two debt settlements: First, a proposed settlement of $168,300 through the issuance of 3,366,000 common shares at $0.05 per share, pending TSX Venture Exchange approval. Second, the completion of a previously announced debt settlement of $113,000 through the issuance of 2,825,000 common shares at $0.04 per share, with shares subject to a hold period until May 4, 2025.
Positive
- Addition of experienced healthcare and technology executive to Advisory Board
- Settlement of $281,300 total debt through share issuance
Negative
- Dilution of shareholder value through issuance of 6,191,000 new shares for debt settlement
News Market Reaction
On the day this news was published, TBRIF gained 24.48%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Announces Shares for Debt Settlements
Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the addition of Steve Raysely to its Advisory Board. With deep experience in healthcare and technology sales, marketing and operations, Mr. Raysely brings a wealth of expertise to the Company's growing advisory team.
Steve Raysely is a distinguished senior executive and strategic advisor with over two decades of experience driving growth, innovation, and operational excellence. Known for his ability to scale businesses and build dynamic go-to-market strategies, Mr. Raysely expertise encompasses leadership in medical device sales, AI-driven healthcare solutions, and strategic partnership development.
As a trusted advisor to Therma Bright, Mr. Raysely will provide invaluable strategic counsel on product market positioning, commercial expansion, and the deployment of emerging health technologies. He draws upon a proven track record of identifying high-growth opportunities, optimizing customer experience and delivering sustained revenue growth.
"We are pleased that Steve has agreed to join our Advisory Board," said Rob Fia, CEO of Therma Bright. "His executive advisory approach centers on scaling distribution operations, pioneering sales, and seamlessly integrating advanced technologies to meet evolving market needs. His visionary leadership and outcome-driven approach make him a pivotal asset to Company's pursuit of transforming innovation into wellness."
Mr. Raysely joins Mr. Sommerville and Mr. Raimondo on the Advisory Board; all of whom are leveraging their networks to introduce Therma Bright, the Venowave VW5 and its other innovative diagnostic and medical device technologies to the U.S. healthcare marketplace.
Debt Settlements
The Company also announces that it has negotiated debt settlements with arm's length creditors. Subject to acceptance by the TSX Venture Exchange, the Company proposes to settle aggregate debt of
Therma Bright also announces that further to its press release of January 3, 2025, it has now issued an aggregate of 2,825,000 common shares at a deemed price of
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events and related information such as future sales of Venowave as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239529
FAQ
What is the total value of debt being settled by Therma Bright (TBRIF) in February 2025?
How many new shares is TBRIF issuing for its February 2025 debt settlements?
When does the hold period expire for TBRIF's January 2025 debt settlement shares?
What expertise does Steve Raysely bring to Therma Bright's Advisory Board?
